Alibaba Health Information Technology (241) H1 2025 earnings summary

Executive summary

• Revenue rose 10.2% year-over-year to RMB14,274 million for FY25 H1, with net profit up 72.8% to RMB769 million and adjusted net profit up 52.2% to RMB978 million.

• Platform served over 300 million annual active users, with SKUs up 20% to 78 million and merchants up 25% to over 40,000.

• Operational efficiency gains and digital upgrades significantly enhanced profitability.

• Continued expansion of digital healthcare services, with over 230,000 licensed professionals providing online consultations.

• Tmall Healthcare Platform GMV and SKUs both showed strong growth.

Financial highlights

• Gross profit increased 23.2% year-over-year to RMB3,534 million, with gross margin up from 22.1% to 24.8%.

• Pharmaceutical direct sales revenue grew 5.9% to RMB12,121 million, while e-commerce platform revenue surged 67.5% to RMB1,710 million.

• Healthcare and digital services revenue declined 9.4% to RMB442 million.

• Fulfillment costs as a percentage of direct sales revenue fell to 10.4% from 10.9% year-over-year.

• Basic EPS was RMB4.79 cents, up from RMB3.30 cents year-over-year.

Outlook and guidance

• Policy support for private economy and "Internet + Healthcare" expected to drive industry growth.

• Plans to further digitalize healthcare services, expand cloud-based infrastructure, and leverage AI in e-commerce and medical fields.

• Aims to become a digital health management company serving 500 million people within five years.